Abstract:In the early 1960's the first human coronaviruses (designated 229E and OC43) were identified as etiologic agents of the common cold, to be followed by the subsequent isolation of three more human coronaviruses similarly associated with cold-like diseases. In contrast to these mild coronaviruses, over the last 20 years there have been three independent events of emergence of pandemic severe and acute life-threatening respiratory diseases caused by three novel beta-coronaviruses, SARS CoV, MERS CoV and most recently SARS CoV2. Whereas the first SARS CoV appeared in November 2002 and spontaneously disappeared by the summer of 2003, MERS CoV has continued persistently to spill over to humans via an intermediary camel vector, causing tens of cases annually. Although human-to-human transmission is rare, the fatality rate of MERS CoV disease is remarkably higher than 30%. COVID-19 however, is fortunately much less fatal, despite that its etiologic agent, SARS CoV2, is tremendously infectious, particularly with the recent evolution of the Omicron variants of concern (BA.1 and BA.2). Of note, MERS CoV prevalence in camel populations in Africa and the Middle East is extremely high. Moreover, MERS CoV and SARS CoV2 co-exist in the Middle East and especially in Saudi Arabia and the UAE, where sporadic incidences of co-infection have already been reported. Co-infection, either due to reverse spill -over of SARS CoV2 to camels or in double infected humans could lead to recombination between the two vi-ruses, rendering either SARS CoV2 more lethal or MERS CoV more transmittable. In an attempt to prepare for what could develop into a catastrophic event, we have focused on developing a novel epitope-based immunogen for MERS CoV. Implementing combinatorial phage-display conformer libraries, the Receptor Binding Motif (RBM) of the MERS CoV Spike protein has been successfully reconstituted and shown to be recognized by a panel of seven neutralizing monoclonal antibodies.

A Truncated Receptor-Binding Domain of Mers-Cov Spike Protein Potently Inhibits Mers-Cov Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein.

Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27

Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.

Functional reconstitution of the MERS CoV receptor binding motif

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

Junctional and Allele-Specific Residues Are Critical for MERS-CoV Neutralization by an Exceptionally Potent Germline-Like Antibody

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.

Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans

Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From A Recovered Patient

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.

Structural Definition of a Neutralization Epitope on the N-terminal Domain of MERS-CoV Spike Glycoprotein

Optimization of Antigen Dose for a Receptor-Binding Domain-Based Subunit Vaccine Against MERS Coronavirus.

Complex Structure of Mers-Cov Spike Glycoprotein with Human Receptor Dpp4

Corrigendum: The cholesterol-binding sequence in monomeric C-reactive protein binds to the SARS-CoV-2 spike receptor-binding domain and blocks interaction with Angiotensin-converting enzyme 2